You are here

ASH

ASH: Pfizer, swimming in crowded waters, eyes wide impact for sickle cell, hemophilia assets

Fierce Biotech

Sun, 12/10/23 - 11:12 pm

sickle cell disease

Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout

Biopharma Dive

Sun, 11/10/19 - 07:56 pm

Bristol-Myers Squibb

Waiting for bluebird bio to Sing at ASH

Motley Fool

Sat, 11/10/18 - 12:05 pm

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

Endpoints

Fri, 11/24/17 - 09:25 am

chronic lymphocytic leukemia

9 Notable Biotechs Presenting At This Year's ASH Meeting

Yahoo

Tue, 11/7/17 - 09:56 am

Ziopharm Oncology

Spark Therapeutics

Juno Therapeutics

Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission

Endpoints

Thu, 11/2/17 - 09:56 am

Agios Pharmaceuticals

#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status

Endpoints

Wed, 11/1/17 - 06:52 pm

Juno Therapeutics

bluebird bio Pauses During 2017 Data Blitz

Motley Fool

Mon, 08/7/17 - 05:59 pm

Novartis' Big News at ASH? It's Still in the CAR-T Race

Motley Fool

Fri, 12/16/16 - 11:28 am

As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum

Fierce Pharma

Sat, 12/3/16 - 09:21 am

2 Pharmas That Should Move After 55th ASH Meeting

Seeking Alpha

Wed, 11/20/13 - 11:01 am

Ariad Pharmaceuticals

The Winner of ASH 2010: Seattle Genetics

Seeking Alpha

Mon, 12/20/10 - 09:59 am

Seattle Genetics

Celgene in ASH Abstract Spotlight

TheStreet.com

Tue, 11/10/09 - 10:34 am